ASX Announcement Quarterly Cash Flow Statement & Operational Highlights Highlights: • HREC approves active controlled comparator study design for pivotal Phase 3 ® clinical trial of RECCE 327 Topical Gel (R327G) in Diabetic Foot Infections (DFI) in Australia ® • Vietnamese patent granted for...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- License and Commercialisation Agreement in AUS/NZ for R327G
- Independent Review of Indonesian Phase 3 R327G Trial Data
- Amendments to Debt Facility with Avenue Capital Group
- Appendix 4E and FY26 Annual Report
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals